Smith Karen L.

Smith Karen L. is listed in filings as Director at Skye Bioscience, Inc.. This profile follows SEC Form 4 activity through Apr 2, 2026, including sale activity. Recent filings connect the profile to Skye Bioscience, Inc. (SKYE), Sangamo Therapeutics, Inc. (SGMO), Context Therapeutics Inc. (CNTX), and Aurinia Pharmaceuticals Inc. (AUPH). The current snapshot covers public activity from Jul 5, 2024 to Apr 2, 2026. Reported amounts are shown as $46.1K to $80.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.